Digoxin as a Treatment Option for Heart Failure with Reduced Ejection Fraction

Authors

  • Omveer Singh Assistant Professor, Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, India
  • Mamta Naagar Assistant Professor, Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, India
  • Manish Kumar Maity Student, Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, India
  • Shailesh Sharma Professor, Dr. K. N. Modi University, Newai, India

Keywords:

Digoxin, Heart Failure (HF), Ejection fraction (EF), Patients

Abstract

Digoxin is a cardiovascular drug obtained from the plant leaf of Digitalis lanata. Digoxin has a long history of usage in cardiovascular treatment. There is ongoing discussion over this drug's mode of action and therapeutic effectiveness. Positive inotropic and neurohormonal modulation effects of digoxin are found. Since the advent of beta-blockers and aldosterone antagonists as components of modern heart failure therapy, the rate of digoxin prescriptions has fallen. American and European heart failure therapy recommendations still include digoxin as a possible course of action. Since the first Digitalis Investigation Group trial findings were made public, observational studies and post hoc analyses have raised concerns about the clinical efficacy and long-term safety of digoxin. In this review, we analyze the clinical evidence, effectiveness and the safety of digoxin in patients with heart failure and lower ejection fraction.

Downloads

Download data is not yet available.

Downloads

Published

18-11-2022

How to Cite

[1]
O. Singh, M. Naagar, M. K. Maity, and S. Sharma, “Digoxin as a Treatment Option for Heart Failure with Reduced Ejection Fraction”, IJRAMT, vol. 3, no. 11, pp. 31–37, Nov. 2022.

Issue

Section

Articles